The effect of proton pump-inhibiting drugs on mineral metabolism

American Journal of Gastroenterology

Volumn 104, Issue SUPPL. 2, 2009, Pages

  Insogna, Karl L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CARBONATE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

AREA UNDER THE CURVE; BONE DENSITY; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM ANTAGONISM; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HEMODIALYSIS PATIENT; HIP FRACTURE; HUMAN; INTESTINE ABSORPTION; MINERAL METABOLISM; PRIORITY JOURNAL; SHORT SURVEY; STOMACH ACID;

ANTI-ULCER AGENTS; BONE AND BONES; BONE DENSITY; CALCIUM; FRACTURES, SPONTANEOUS; HIP FRACTURES; HUMANS; INTESTINAL ABSORPTION; OSTEOPOROSIS; PROTON PUMP INHIBITORS;

EID: 61949402676     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.44     Document Type: Short Survey

References (12)

1. Graziani G, Badalamenti S, Como G et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 2002;91:474-9.
2. Hardy P, Sechet A, Hottelart C et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998;22:569-73.
3. Graziani G, Como G, Badalamenti S et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995;10:1376-80.
4. O'Connell MB, Madden DM, Murray AM et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-81.
5. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985;313:70-3.
6. Serfaty-Lacrosniere C, Wood RJ, Voytko D et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995;14:364-8.
7. Mizunashi K, Furukawa Y, Katano K et al. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21-5.
8. Kocsis I, Arato A, Bodanszky H et al. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int 2002;71:129-32.
9. Adachi Y, Shiota E, Matsumata T et al. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int 1998;62:283-5.
10. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53.
11. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83.
12. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9.